TELA Bio, Inc. (TELA) stock
TELANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.76+0.00 (+0.07%)
Close on Nov 17, 2026Market cap $34.21MP/E –Yield –
TELA Bio r&d expenses
Research and development expenses are spending on new products and technology.
TELA Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.54M, up 8.0% year over year. For fiscal 2025 it was $9.22M, up 4.6% from the year before. The highest annual figure on record is $9.62M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.22M | +4.6% |
| FY2024 | Dec 31, 2024 | $8.81M | -8.4% |
| FY2023 | Dec 31, 2023 | $9.62M | +7.6% |
| FY2022 | Dec 31, 2022 | $8.94M | +32.5% |
| FY2021 | Dec 31, 2021 | $6.74M | +58.5% |
| FY2020 | Dec 31, 2020 | $4.26M | +2.5% |
| FY2019 | Dec 31, 2019 | $4.15M | -4.3% |
| FY2018 | Dec 31, 2018 | $4.34M | -25.0% |
| FY2017 | Dec 31, 2017 | $5.79M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.72M | +23.6% |
| Q1 FY2026 | Mar 31, 2026 | $2.34M | -7.8% |
| Q4 FY2025 | Dec 31, 2025 | $2.13M | +4.9% |
| Q3 FY2025 | Sep 30, 2025 | $2.35M | +13.5% |
| Q2 FY2025 | Jun 30, 2025 | $2.20M | -5.2% |
| Q1 FY2025 | Mar 31, 2025 | $2.54M | +6.1% |
| Q4 FY2024 | Dec 31, 2024 | $2.03M | -24.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.07M | -12.7% |
| Q2 FY2024 | Jun 30, 2024 | $2.32M | -7.6% |
| Q1 FY2024 | Mar 31, 2024 | $2.39M | +16.6% |
| Q4 FY2023 | Dec 31, 2023 | $2.69M | -1.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.37M | +12.7% |
| Q2 FY2023 | Jun 30, 2023 | $2.51M | +19.6% |
| Q1 FY2023 | Mar 31, 2023 | $2.05M | +2.2% |
| Q4 FY2022 | Dec 31, 2022 | $2.73M | +58.0% |
| Q3 FY2022 | Sep 30, 2022 | $2.10M | +49.2% |
| Q2 FY2022 | Jun 30, 2022 | $2.10M | +8.9% |
| Q1 FY2022 | Mar 31, 2022 | $2.01M | +19.5% |
| Q4 FY2021 | Dec 31, 2021 | $1.73M | +48.3% |
| Q3 FY2021 | Sep 30, 2021 | $1.41M | +17.3% |
| Q2 FY2021 | Jun 30, 2021 | $1.93M | +97.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.68M | +84.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.16M | +10.2% |
| Q3 FY2020 | Sep 30, 2020 | $1.20M | -27.6% |
| Q2 FY2020 | Jun 30, 2020 | $979.00K | +0.2% |
| Q1 FY2020 | Mar 31, 2020 | $912.00K | -12.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.06M | – |
| Q1 FY2019 | Mar 31, 2019 | $1.66M | – |
| Q4 FY2018 | Dec 31, 2018 | $977.00K | – |
| Q3 FY2018 | Sep 30, 2018 | $1.04M | – |
See a number that looks wrong?